Cabozantinib: Phase I data

Interim data from an open-label, dose-escalation, Japanese Phase I trial in 14 patients with advanced solid tumors showed that once-daily 40, 60 and 80 mg cabozantinib produced confirmed partial responses in 4 of 5 patients with non-small cell lung cancer (NSCLC) and 8 cases of stable disease. The MTD was once-daily 60 mg cabozantinib and 2 patients reported a dose-limiting toxicity (DLT) of grade 3 hypertension. The most common grade >=3 adverse events reported were hypertension, neutropenia and palmar-plantar erythrodysesthesia (PPE) syndrome. There were 4 cabozantinib-related serious adverse events reported, including anemia, hematemesis, intestinal obstruction and melena, and 1 unrelated serious adverse event of pleural effusion. Data were presented at the European Society for Medical Oncology meeting in Vienna. ...